No Data
No Data
Jiete Biotech (688026.SH) appoints Xie Feng as the company's financial director
Jet Biotech (688026.SH) announced that the board of directors of the company reviewed and approved the relevant resolution on May 22, 2024...
Jiete Biotech (688026.SH) spent a total of 20065,500 yuan to buy back 1.22% of the company's shares
Jet Biotech (688026.SH) issued an announcement. As of the announcement disclosure date, the company traded through the Shanghai Stock Exchange...
Jet Biotech (688026): Short-term pressure on performance is expected to resume growth in 2024
Incident: The company released its 2023 annual report and 2024 quarterly report. In 2023, it achieved operating income of 463 million yuan (yoy -24.06%) and net profit of 35 million yuan (yoy-60)
Jiete Biotech (688026.SH): 1.22% of the company's shares have been repurchased
Gelonghui, May 6 | Jet Biotech (688026.SH) announced that as of April 30, 2024, the company had repurchased a total of 1,708,861 shares of the company through centralized bidding transactions, accounting for 1.22% of the company's total share capital of 140,363,220 shares. The highest price of the repurchase transaction was 13.13 yuan/share, the lowest price was 11.15 yuan/share, and the total amount of capital paid was RMB 20,065,542.30 (excluding transaction fees such as stamp duty and transaction fees).
Express News | Jiete Biotech: The company's consumables can be used in the field of synthetic biology
Jet Convertible Bonds: Expected to meet the conversion price correction conditions
Guangzhou Jet Biofiltration Co., Ltd. announced that from April 16, 2024 to April 29, 2024, the closing price of the company's stock was lower than 85% of the current share conversion price for 10 trading days, which is expected to trigger downward revision conditions for the “Jet Bonds” conversion price.
No Data